Xenetic Biosciences (XBIO) investor relations material

Executive summary

• Advanced DNase technology for immuno-oncology, targeting difficult-to-treat cancers, with ongoing preclinical and translational research collaborations and manufacturing readiness for future clinical development.

• Collaboration partner received approval for an exploratory study of DNase I with anti-CD19 CAR T cells in large B-cell lymphoma.

• Initiated a formal strategic review process, considering options such as sale, merger, or business combination to maximize shareholder value.

• No regulatory approvals for drug candidates yet; ongoing royalty revenue from legacy PolyXen technology.

Financial highlights

• Revenue for Q1 2026 was $0.81M, up 36% year-over-year, driven by increased royalties from Takeda and sublicense agreements.

• Net loss for Q1 2026 was $0.46M, a 49.5% improvement from Q1 2025's $0.90M loss.

• Operating expenses decreased 14.8% year-over-year, mainly due to lower R&D costs.

• R&D expenses decreased 25% year-over-year to $0.66M.

• Cash balance at March 31, 2026 was $7.3M, with working capital of $6.6M.

Outlook and guidance

• Existing resources expected to fund operations for at least 12 months from the reporting date.

• Additional long-term capital will be needed to pursue business initiatives; access to future financing is subject to market and operational factors.

• Focus remains on advancing DNase I into clinical trials for pancreatic carcinoma and metastatic solid tumors.

• Ongoing strategic review process may impact future business direction.